Questcor Pharmaceuticals Inc

Questcor Pharmaceuticals — Q1 2013 Earnings Presentation

10 slides from Questcor Pharmaceuticals's earnings presentation, May 6, 2013

  1. Slide 1: First Quarter 2013 Conference Call

    NASDAQ: QCOR First Quarter 2013 Conference Call Conference Call Logistics

  2. Slide 2: Conference Call Logistics

    Conference Call Logistics * Today’s webcast, accompanying slide presentation and archived replay is available online at * Telephone replay is available by dialing: — U.S.: (855) 859-2056. — International: (404) 537-3406. — Passcode: 34200996 (QR QUESTCOR®

  3. Slide 3: Safe Harbor Statement

    Safe Harbor Statement Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performanc

  4. Slide 4: Q1 Financial Results and Q2 Trends

    Q1 Financial Results and Q2 Trends · 4,830 vials shipped · $135.1M in net sales · $0.65 GAAP diluted EPS; $0.76 Non-GAAP diluted EPS · In April, 2,550 vials shipped (record month) · In April, Acthar Rxs increased, including MS Note: See Reconciliation of Non-GAAP Adjusted Financial Disclosure slide

  5. Slide 5: Paid Rx Comparison

    Paid Rx Comparison Q1 – 2013 Q1 – 2012 Q4 – 2012 NS 385 - 395 ?56% ?5% MS 1,015 - 1,025 ?3% ?17% IS 155 - 165 ?14% ?11% Rheumatology 140 - 150 N/M ?58% · Includes prescriptions covered by commercial carriers, Medicare, Medicaid and Tricare in all periods regardless of the rebate percentage applicabl

  6. Slide 6: Stable Reimbursement Environment

    Stable Reimbursement Environment · MDs typically reserve Acthar for when another FDA-approved treatment alternative is needed, usually after first-line therapy · Serious, difficult-to-treat medical conditions · Coverage decisions are determined on a case-by-case basis, considering patient condition,

  7. Slide 7: The Emerging Science Behind Acthar

    The Emerging Science Behind Acthar Preclinical and Clinical Studies · Understanding the biological properties of Acthar · Specific biochemical pathways, cells, and tissues · Immunomodulation and anti-inflammatory effects · Further research related to on-label indications · Lupus · Idiopathic Membran

  8. Slide 8: Q1-2013 Financial Results

    Q1-2013 Financial Results Q1 – 2013 Q1 – 2012 Net Sales ($M) $135.1 $96.0 Fully Diluted, GAAP EPS $0.65 $0.58 Fully Diluted, Non-GAAP EPS $0.76 $0.61 Cash flow from operations ($M) $41.5 $40.9 Diluted shares outstanding 60.3 66.5

  9. Slide 9: Reconciliation of Non-GAAP Adjusted Financial Disclosure

    Reconciliation of Non-GAAP Adjusted Financial Disclosure Three Months Ended Three Months Ended 03/31/13 03/31/12 Adjusted net income per share - basic $ 0.79 $ 0.64 Share-based compensation expense (1) (0.07) (0.02) Depreciation and amortization expense (2) (0.03) (0.00) Interest expense associated

  10. Slide 10: First Quarter 2013 Conference Call

    NASDAQ: QCOR First Quarter 2013 Conference Call

Questcor Pharmaceuticals — Q1 2013 Earnings Presentation on 6ix